Lugano, Switzerland, October 6, 2020 - Helsinn, a Swiss pharmaceutical group focused on building quality cancer care and rare diseases products, is pleased to announce that it has received one of Swiss Biotech Association’s Success Stories Awards 2020.
The Swiss Biotech Success Stories Awards highlight significant achievements and honor those who have made important and sustainable contributions to the biotech industry in Switzerland. The recognition is awarded annually and reflects the diversity and variety in the industry sector.
Helsinn was recognized for its broad portfolio of on-market cancer care products and its deep development pipeline, as well as for its development and manufacturing capabilities and contribution to employment in Ticino.
Founded in 1998, the Swiss Biotech Association represents the interests of the Swiss biotech industry to support its members. The association works to secure favorable framework conditions and facilitate access to talents, novel technologies and financial resources.
Switzerland Global Enterprise, as sponsor of the awards, presented Helsinn with the prestigious prize. Switzerland Global Enterprise is an organization which on behalf of the Swiss Confederation (State Secretariat for Economic Affairs SECO) and the Swiss cantons, promotes export and investments by helping its clients to realize new potential for their international businesses and thus to strengthen Switzerland as an economic hub.
Dominik Escher, President of the Swiss Biotech Association, commented: “Helsinn is a true success story for Switzerland, Founded in 1976 and still a family-run business, the company has successfully in-licensed and further developed several products in cancer care. Today, Helsinn invests 25% of its profit for further research and development and by that expands its cancer care portfolio, thus helping more patients in the future.”
Riccardo Braglia, Helsinn Group Vice Chairman and CEO, commented: “We’re honored to receive this award and to be recognized as a Swiss biotech success story for our outward look at innovation and unwavering determination to push boundaries in healthcare. Helsinn was founded back in 1976 in Ticino, and although international in outlook, Switzerland continues to be the heart of our company, as a world-leading hub for biopharma.”
Giorgio Calderari, Group General Manager and Chief Operating Officer, said: “We’re very pleased that the Swiss Biotech Association has recognized us for our commitment to improving the lives of those living with cancer. The team at Helsinn is always striving to find innovative solutions for cancer patients, with our business strategy underpinned by our cores values of quality, integrity and respect.”
About the Helsinn Group
Helsinn is a privately-owned Swiss Pharma Company which, since 1976, has been improving the lives of patients, guided by core family values of respect, integrity and quality. The Group has an extensive portfolio of marketed innovative cancer and rare disease therapies, a robust drug development pipeline and ambitions to further accelerate its growth through in-licensing and acquisition to address unmet medical needs. Helsinn operates a unique integrated licensing business model, achieving success with over 80 long-standing partners in 190 countries, who share our values. The Group’s pharmaceutical business (Helsinn Healthcare) is headquartered in Lugano, Switzerland with operating subsidiaries in the U.S. (Helsinn Therapeutics US) and China (Helsinn Pharmaceuticals China) which market the Group’s products directly in these countries. The Group has additional operating subsidiaries in Switzerland (Helsinn Advanced Synthesis, an active pharmaceutical ingredient manufacturer) and Ireland (Helsinn Birex Pharmaceuticals, a drug product manufacturer). Helsinn Investment Fund was created to enhance the future of healthcare by providing funding and strategic support to innovative companies.
Helsinn Group plays an active and central role in promoting social transformation in favor of people and the environment. Corporate social responsibility is at the heart of everything we do which is reinforced in the company's strategic plan by a commitment to sustainable growth.
To learn more about Helsinn Group please visit www.helsinn.com
Helsinn Group Media Contact
Group Head of Communication
Tel: +41 (0) 91 985 21 21